TNYA vs. CCCC, ADAP, SRNE, ABOS, FUSN, IVVD, ARYD, FENC, GNFT, and OCGN
Should you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include C4 Therapeutics (CCCC), Adaptimmune Therapeutics (ADAP), Sorrento Therapeutics (SRNE), Acumen Pharmaceuticals (ABOS), Fusion Pharmaceuticals (FUSN), Invivyd (IVVD), ARYA Sciences Acquisition Corp IV (ARYD), Fennec Pharmaceuticals (FENC), Genfit (GNFT), and Ocugen (OCGN). These companies are all part of the "biological products, except diagnostic" industry.
Tenaya Therapeutics vs.
C4 Therapeutics (NASDAQ:CCCC) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.
In the previous week, C4 Therapeutics had 2 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 3 mentions for C4 Therapeutics and 1 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.93 beat C4 Therapeutics' score of 0.79 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.
C4 Therapeutics has a beta of 2.24, suggesting that its stock price is 124% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500.
80.3% of C4 Therapeutics shares are held by institutional investors. 14.2% of C4 Therapeutics shares are held by company insiders. Comparatively, 34.2% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
C4 Therapeutics currently has a consensus price target of $15.44, suggesting a potential upside of 342.53%. Tenaya Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 614.29%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than C4 Therapeutics.
C4 Therapeutics received 8 more outperform votes than Tenaya Therapeutics when rated by MarketBeat users. However, 63.16% of users gave Tenaya Therapeutics an outperform vote while only 39.22% of users gave C4 Therapeutics an outperform vote.
Tenaya Therapeutics has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.
Tenaya Therapeutics has a net margin of 0.00% compared to C4 Therapeutics' net margin of -412.19%. C4 Therapeutics' return on equity of -38.94% beat Tenaya Therapeutics' return on equity.
Summary
Tenaya Therapeutics beats C4 Therapeutics on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Tenaya Therapeutics Competitors List